Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0W5ZU
|
||||
Former ID |
DIB007865
|
||||
Drug Name |
Antova
|
||||
Synonyms |
Ruplizumab
|
||||
Indication | Thrombocytopenia [ICD9: 287.3, 287.4, 287.5; ICD10:D69.6, P61.0] | Terminated | [546796] | ||
Company |
Biogen Idec
|
||||
Target and Pathway | |||||
Target(s) | Tumor necrosis factor ligand superfamily member 5 | Target Info | Modulator | ||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
NF-kappa B signaling pathway | |||||
Cell adhesion molecules (CAMs) | |||||
T cell receptor signaling pathway | |||||
Intestinal immune network for IgA production | |||||
Malaria | |||||
Toxoplasmosis | |||||
Asthma | |||||
Autoimmune thyroid disease | |||||
Systemic lupus erythematosus | |||||
Allograft rejection | |||||
Primary immunodeficiency | |||||
Viral myocarditis | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.